GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (NAS:SYBX) » Definitions » Shiller PE Ratio

Synlogic (Synlogic) Shiller PE Ratio : (As of May. 03, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Synlogic Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Synlogic Shiller PE Ratio Historical Data

The historical data trend for Synlogic's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlogic Shiller PE Ratio Chart

Synlogic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synlogic Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Synlogic's Shiller PE Ratio

For the Biotechnology subindustry, Synlogic's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synlogic's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synlogic's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Synlogic's Shiller PE Ratio falls into.



Synlogic Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Synlogic's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Synlogic's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.582/129.4194*129.4194
=-1.582

Current CPI (Dec. 2023) = 129.4194.

Synlogic Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201409 -71.804 100.428 -92.532
201412 -95.359 99.070 -124.572
201503 -56.657 99.621 -73.604
201506 -35.781 100.684 -45.993
201509 -49.007 100.392 -63.177
201512 -44.812 99.792 -58.116
201603 -33.600 100.470 -43.281
201606 -28.350 101.688 -36.081
201609 -27.300 101.861 -34.686
201612 -43.801 101.863 -55.650
201703 -25.200 102.862 -31.706
201706 -47.250 103.349 -59.169
201709 -24.900 104.136 -30.946
201712 -11.100 104.011 -13.812
201803 -8.250 105.290 -10.141
201806 -8.850 106.317 -10.773
201809 -6.450 106.507 -7.838
201812 -7.050 105.998 -8.608
201903 -7.650 107.251 -9.231
201906 -6.750 108.070 -8.084
201909 -5.850 108.329 -6.989
201912 -5.550 108.420 -6.625
202003 -6.900 108.902 -8.200
202006 -6.600 108.767 -7.853
202009 -5.400 109.815 -6.364
202012 -5.850 109.897 -6.889
202103 -5.400 111.754 -6.254
202106 -4.200 114.631 -4.742
202109 -4.350 115.734 -4.864
202112 -3.150 117.630 -3.466
202203 -3.300 121.301 -3.521
202206 -3.300 125.017 -3.416
202209 -3.730 125.227 -3.855
202212 -3.540 125.222 -3.659
202303 -3.450 127.348 -3.506
202306 -3.150 128.729 -3.167
202309 -2.570 129.860 -2.561
202312 -1.582 129.419 -1.582

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Synlogic  (NAS:SYBX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Synlogic Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Synlogic's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Synlogic (Synlogic) Business Description

Traded in Other Exchanges
Address
301 Binney Street, Suite 402, Cambridge, MA, USA, 02142
Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.
Executives
Michael Vangsted Jensen officer: Chief Financial Officer 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Aoife Brennan officer: Chief Medical Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Antoine Awad officer: Chief Operating Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Lisa Kelly-croswell director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Michael F. Burgess director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Richard P Shea director C/O MOMENTA PHARMACEUTICALS, INC., 43 MOULTON STREET, CAMBRIDGE MA 02138
Gregg Beloff officer: See Remarks C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Richard J. Riese officer: Chief Medical Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Ginkgo Bioworks, Inc. 10 percent owner 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Scott Eric Plevy officer: Chief Scientific Officer 301 BINNEY STREET, #402, C/O SYNLOGIC, INC., CAMBRIDGE MA 02142
Paul Francis Miller officer: Chief Scientific Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Patricia N. Hurter director C/O SYNLOGIC, INC., 301 BINNEY ST., SUITE 402, CAMBRIDGE MA 02142
Andrew Gengos officer: See Remarks 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Todd Shegog officer: See Remarks 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139